LynxBio is transforming the development of blood cancer therapies and delivering precise patient management by identifying the most promising therapeutic options.
Creates an ex vivo model of a patient's cancer by incorporating both tumor and non-tumor cells
Cellular response readout able to be integrated with complementary technologies
Seamless integration into clinical workflow using standard of care biopsy
Actionable results 3 days after biopsy
Identification of all patients as either clinically responsive or non-responsive in first clinical trial to a common blood cancer drug